Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism for its action is that it prevents the proteasomal degradation of proapoptotic proteins, leading to enhanced apoptosis. Although...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Spandidos Publications
2015
|
| On-line přístup: | http://psasir.upm.edu.my/id/eprint/36675/1/Bortezomib%20attenuates%20HIF-1-%20but%20not%20HIF-2-mediated%20transcriptional%20activation.pdf |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|